No Data
Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology to Present at Upcoming Investor Conferences in May
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
No Data